← ANALYST RATINGS · TIPRANKS
Personalis (PSNL): analyst forecast and price target
Analyst consensus
Hold0 Buy4 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $16.25, the highest $16.25, the lowest $16.25. The average is +3.8% from the last price of $15.65.
Analyst ratings 8
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $18.00 → $16.50−8.3% | Hold | +5.4% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $18.00 → $16.50−8.3% | Hold | +5.4% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $18.00 → $16.00−11.1% | Hold | +2.2% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $17.00 → $16.00−5.9% | Hold | +2.2% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $18.50 → $16.50−10.8% | Hold | +5.4% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $17.50 → $17.00−2.9% | Hold | +8.6% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | — | Hold | — | Downgrade | 06.10.26on TipRanks 06:05 | −2.8%next day +0.1% · 5 days −1.0% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $17.00 → $18.00+5.9% | Hold | +15.0% | Reiterated | 06.09.26on TipRanks 13:06 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $16.50 → $18.00+9.1% | Hold | +15.0% | Reiterated | 06.09.26on TipRanks 13:06 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $16.00 → $18.00+12.5% | Hold | +15.0% | Reiterated | 06.09.26on TipRanks 13:06 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $15.50 → $17.00+9.7% | Hold | +8.6% | Reiterated | 06.09.26on TipRanks 13:06 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $17.00 → $18.50+8.8% | Hold | +18.2% | Reiterated | 06.09.26on TipRanks 13:06 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $16.50 → $17.50+6.1% | Hold | +11.8% | Reiterated | 06.09.26on TipRanks 13:06 | — | |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | $16.25 | Hold | +3.8% | Downgrade | 24.08.26on TipRanks 09:06 | −6.9%next day +0.8% · 5 days −2.1% | ↗ |
| Thomas Flaten★★★★★★★★★★#1650 · hits 47% · avg +8.9% | Lake Street | $16.25 | Hold | +3.8% | Reiterated | 21.08.26on TipRanks 09:11 | +8.5%next day −6.9% · 5 days −7.6% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | — | Hold | — | Reiterated | 06.08.26on TipRanks 02:55 | −3.5%next day +8.1% · 5 days +9.5% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $11.00 → $16.25+47.7% | Buy | +3.8% | Reiterated | 20.07.26on TipRanks Jul 24 05:09 | −13.2%next day −0.1% · 5 days −9.8% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $10.00 → $18.00+80.0% | Buy | +15.0% | Assigned | 15.07.26on TipRanks 09:01 | +4.7%next day −0.8% · 5 days −20.0% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $9.00 → $13.00+44.4% | Hold | −16.9% | Assigned | 09.07.26on TipRanks 07:47 | +3.0%next day −4.4% · 5 days +6.5% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $13.00 | Buy | −16.9% | Reiterated | 07.05.26on TipRanks May 8 07:30 | −1.0%next day −1.0% · 5 days +9.8% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Personalis
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.95 at a price of $16.28 (−2.0%); now: $16.25 at $15.65 (+3.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 0 | 0 | 0 |
| Buy | 3 | 2 | 5 | 3 | 3 | 0 |
| Hold | 2 | 1 | 5 | 8 | 8 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.26 (from $-0.32 to $-0.23). Last quarter: $-0.30.
Sales
Next quarter’s sales estimate — $22M (from $21M to $22M). Last quarter: $22M.
Best top-analyst consensus in the sector · Healthcare
About Personalis
- CEO: Christopher Hall
- Employees: 260
- 6600 Dumbarton Circle, Fremont, CA, 94555, US
- www.personalis.com
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Data from the stock’s TipRanks forecast page, read 97 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗